NASDAQ · AQST
Healthcare · Drug Manufacturers - Specialty & Generic
$4.00
Down-$0.02 (-0.38%)
Updated Oct 26, 2026, 3:05 PM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AQST
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
AQST closed at $4.00 after 20 trading sessions, down 15.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $4.08 | $4.135 | $3.97 | $4.00 | 1.75M |
| Oct 22, 2026 | $4.10 | $4.1599 | $4.04 | $4.13 | 1.85M |
| Oct 21, 2026 | $4.08 | $4.185 | $4.0201 | $4.08 | 1.57M |
| Oct 20, 2026 | $3.83 | $4.13 | $3.79 | $4.05 | 2.26M |
| Oct 19, 2026 | $3.80 | $3.85 | $3.65 | $3.83 | 3.34M |
| Oct 16, 2026 | $4.09 | $4.10 | $3.75 | $3.78 | 5.25M |
| Oct 15, 2026 | $4.67 | $4.715 | $3.99 | $4.06 | 5.47M |
| Oct 14, 2026 | $4.73 | $4.73 | $4.57 | $4.61 | 1.6M |
| Oct 13, 2026 | $4.80 | $4.81 | $4.67 | $4.67 | 1.4M |
| Oct 12, 2026 | $4.77 | $4.89 | $4.734 | $4.81 | 957.52K |
| Oct 9, 2026 | $4.78 | $4.975 | $4.74 | $4.78 | 1.69M |
| Oct 8, 2026 | $4.62 | $4.85 | $4.55 | $4.76 | 2.32M |
| Oct 7, 2026 | $4.58 | $4.665 | $4.5301 | $4.62 | 1.36M |
| Oct 6, 2026 | $4.62 | $4.645 | $4.46 | $4.61 | 1.21M |
| Oct 5, 2026 | $4.57 | $4.61 | $4.455 | $4.57 | 1.09M |
| Oct 2, 2026 | $4.53 | $4.595 | $4.425 | $4.55 | 2.27M |
| Oct 1, 2026 | $4.60 | $4.61 | $4.435 | $4.44 | 2.69M |
| Sep 30, 2026 | $4.73 | $4.74 | $4.615 | $4.63 | 2.41M |
| Sep 29, 2026 | $4.70 | $4.75 | $4.55 | $4.67 | 1.71M |
| Sep 28, 2026 | $4.64 | $4.775 | $4.57 | $4.75 | 1.28M |
The latest Smart Investors Daily articles mentioning AQST.
Company
Market Activity
Research & News
AQST research
Company profile and research snapshot.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
| Nov 7, 2025 | Piper Sandler | Overweight | — |
| Oct 9, 2025 | JMP Securities | Market Outperform | — |
| Sep 8, 2025 | Oppenheimer | Outperform | — |
| Jun 17, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 16, 2026
Aquestive Therapeutics is upgraded to a Buy, anticipating Anaphylm approval and potential >$250m annual revenue by 2030. Click to read more on AQST.
Yahoo · Oct 15, 2026
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery techno
Benzinga · Oct 15, 2026
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned
Benzinga · Oct 14, 2026
Eton Pharmaceuticals licenses Aquestive’s LIBERVANT buccal film for U.S. seizure cluster treatment, with launch set for April 2027.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AQST.
